对林奇综合征的新见解:叙述性审查
概括
林奇综合征增加了由于DNA不匹配修复缺陷导致的癌症风险. 本综述详细介绍了遗传原因,诊断进展以及与结直肠,子宫内膜和不太常见的前列腺/丸癌的联系,指导了量身定制的预防.
科学领域:
- 遗传学和瘤学研究
- 分子生物学分子生物学
背景情况:
- 林奇综合征是一种遗传性癌症倾向,源于DNA不匹配修复 (MMR) 基因缺陷 (MLH1,MSH2,MSH6,PMS2,EPCAM).
- 它显著增加了结直肠和子宫内膜癌的风险,新出现的证据将其与其他恶性瘤联系起来.
结论:
- 准确识别林奇综合征对于实施量身定制的监测和预防措施至关重要.
- 了解林奇综合征相关癌症的全谱,包括不太常见的癌症,对于有效的风险管理至关重要.
- 多学科方法对于管理林奇综合征患者和减轻其癌症风险至关重要.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K


